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We investigated the molecular epidemiology of extended spectrum β-lactamase 
(ESBL) producing Klebsiella pneumoniae isolates derived from the teaching hospi-
tals of University of Pécs, Pécs, Hungary in the time period 2004–2008. Molecular 
typing, antimicrobial susceptibility testing, detection of common β-lactamase genes 
(blaCTX-M, blaTEM and blaSHV) and virulence associated traits (hypermucoviscosity, 
magA, k2a, rmpA, siderophores, type 1 and 3 fi mbria, biofi lm formation, serum re-
sistance) were performed for 102 isolates. The results showed the presence of three 
major ciprofl oxacin resistant CTX-M-15 producing clones (ST15 n = 69, ST101 n = 10, 
and ST147 n = 9), of which ST15 was predominant and universally widespread. Con-
sidering distribution in time and place, ST101 and ST147 were detected at fewer in-
patient units and within a narrower time frame, as compared to ST15. Beside major 
clones, eleven minor clones were identifi ed, and were shown to harbour the follow-
ing β-lactamase genes: six clones carried blaCTX-M, four clones harboured blaSHV-5 and 
one clone possessed both blaCTX-M and ESBL type blaSHV. Among the SHV-5 produc-
ing K. pneumoniae clones a novel sequence type was found, namely ST1193, which 
harboured a unique infB allele. Different virulence factor content and peculiar anti-
microbial susceptibility profi le were characteristic for each clone. In contrast to ma-
jor clone isolates, which showed high level resistance to ciprofl oxacin, minor clone 
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isolates displayed signifi cantly lower MIC values for ciprofl oxacin suggesting a role 
for fl uoroquinolones in the dissemination of the major K. pneumoniae clones. This is 
the fi rst description of the CTX-M-15 producing K. pneumoniae clone ST101 in Hun-
gary.
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Introduction
Klebsiella pneumoniae is an opportunistic pathogen, often causing uri-
nary, respiratory and blood stream infections in patients with underlying medi-
cal conditions. The number of multiresistant K. pneumoniae isolates, including 
extended spectrum β-lactamase (ESBL) producing ones, is continuously increas-
ing. According to the European Resistance Surveillance Network report alto-
gether 25.7% of invasive K. pneumoniae isolates in Europe were resistant to third 
generation cephalosporins in 2012, of which 62–100% were supposed to produce 
some sort of ESBL [1]. The most frequently encountered ESBL genes belong to 
the blaCTX-M, blaTEM and blaSHV groups, and their spread is attributed to dissemina-
tion of epidemic resistance plasmids and expansion of successful clones [2].
According to nationwide studies, until 2004 the most common ESBL genes 
in Hungary belonged to the blaSHV group, and were carried on epidemic resist-
ance plasmids [3–5]. In 2005 the spread of three CTX-M-15 producing epidemic 
clones (ST11, ST15 and ST147) were detected across the country [6]. One year 
later the emergence of a fourth epidemic clone (ST274) was observed in various 
regions of the country [7].
Several studies were engaged with the virulence factors of ESBL produc-
ing K. pneumoniae isolates, but the results seem to be limited to the specifi c 
clones and/or resistance plasmids [8–12].
In order to reveal the local characteristics (clonality, antibiotic susceptibil-
ity and virulence factor pattern) we investigated ESBL producing K. pneumoniae 
isolates originating from a single institution (teaching hospitals of University of 
Pécs, Pécs, Hungary) over a 5-year period (2004–2008).
Materials and Methods
Isolates
102 ESBL producing K. pneumoniae isolates were collected between 2004 
and 2008 from human clinical samples (urine n = 57; blood n = 22; lower respira-
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tory tract n = 7; wound, pus or wound aspirate n = 10, vascular catheter n = 3, 
other n = 3) originating from different departments of the Clinical Centre Univer-
sity of Pécs, Pécs, Hungary. The isolates were selected so as to represent the study 
period regarding time and place of collection. Only one isolate per patient was 
included. The identifi cation was performed with standard biochemical proce-
dures [13]. Confi rmation of ESBL production was accomplished with the com-
bined disc (Bio-Rad, Hercules, CA, USA) method [14].
Molecular typing
Clonal relationships were assessed with pulsed-fi eld gel electrophoresis 
(PFGE) as described by others [6]. PFGE was evaluated with unweighted pair 
group method with arithmetic means (UPGMA) using Dice-coeffi cient. Clones 
were defi ned as group of isolates with >85% similar patterns.
Multilocus sequence typing (MLST) was performed for single representa-
tives of seven selected clones (three major clones and four SHV-5 producing mi-
nor clones) [15].
Detection of β-lactamase genes
The presence of blaCTX-M, blaTEM and blaSHV was investigated by polymerase 
chain reaction (PCR) [16–18]. Digestion of blaSHV with NheI was carried out in 
order to identify Gly238→Ser mutation associated with the hydrolysis of third 
generation cephalosporins [19]. Sequencing of blaCTX-M and blaTEM genes were 
performed for single representatives of major clones [17, 20]. The nucleotide se-
quence of blaSHV was determined for single representatives of minor clones, 
where ESBL production was suspected to be solely attributed to SHV-type en-
zymes [18].
Antibiotic susceptibility testing
Susceptibility to amikacin, ciprofl oxacin, gentamicin, tobramycin and tri-
methoprim/sulfamethoxazole was determined by disc (Bio-Rad, Hercules, CA, 
USA) diffusion method according to European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) standards [21].
For minor clone isolates and fi ve representative isolates of major clones 
minimum inhibitory concentration (MIC) of ciprofl oxacin was measured by 
broth microdilution method, and the results were interpreted according to EU-
CAST [21].
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Virulence associated traits
The presence of several factors known or hypothesized to contribute to the 
virulence of K. pneumoniae was investigated. We focused on phenotypic detec-
tion in order to verify gene expression. In those cases where phenotypic tests 
were not available in our department we detected the relevant gene itself by PCR.
Capsular serotypes K1 and K2, which are associated with higher virulence 
potential than other serotypes, were determined with PCR (magA and k2A, re-
spectively) [22, 23]. Hypermucoviscosity phenotype was assessed by string-test, 
and the presence of rmpA was detected by PCR [24]. Measurement of susceptibil-
ity to human serum bactericidal activity was carried out as described by others 
[25]. All isolates were tested in triplicates. The ratio of mean number of colony 
forming units at 60 and 180 minutes after treatment with serum to mean number 
of colony forming units at 0 minute was evaluated for each isolate. The produc-
tion of enterobactin and aerobactin was established in cross feeding bioassay 
[25]. The assay was evaluated after 24 and 48 hours of incubation, and was per-
formed twice for each isolate. PCR was carried out to assess the presence of yer-
siniabactin (irp2-1) and Klebsiella ferric iron uptake gene cluster (kfuB) [26, 27]. 
Yeast cell coagglutination in the presence or absence of 1.0% D-mannose was 
used to detect type 1 fi mbria [28, 29]. Expression of type 3 fi mbria was evaluated 
by agglutination of tannic acid treated bovine erythrocytes [25]. All agglutina-
tion assays were carried out three times. Microtiter plate biofi lm assay was per-
formed in triplicates as described elsewhere [30]. The biofi lm formation capacity 
was approximated by calculating the mean optical density (OD595) for each iso-
late, and isolates with a value of less than 1,000 was considered to be negative in 
the assay.
Statistical methods
In order to test if the three major clones and the minor clones compounded 
were the same in the aspects of virulence associated factor content and antibiotic 
susceptibility rates, probability values (p) were calculated with likelihood ratio 
test for categorical variables and Kruskal–Wallis-test for continuous variables 
(biofi lm, serum resistance). All statistical computations were performed in SPSS 
20. Statistical signifi cance was established as p < 0.05.
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Results
By PFGE the isolates were grouped into fourteen pulsotypes. The results of 
MLST and β-lactamase gene detection are presented in Table I. The distribution 
of the different clones in time and place is shown in Tables II and III. The results 
and statistical analysis of antimicrobial susceptibility testing and possession of 
virulence traits are summarised in Tables IV and V. For eight isolates the results 
of amikacin susceptibility testing was modifi ed from susceptible to intermediate 
as indicated by EUCAST expert rule No. 12.7 [31].








Major clones PT-01 69 ST15 blaSHV (NheI: negative)
blaCTX-M-15
PT-02 10 ST101 blaSHV (NheI: negative)
blaCTX-M-15
blaTEM-1 (in six isolates)
PT-03 9 ST147 blaSHV (NheI: negative)
blaCTX-M
Minor clones PT-04 2 – blaSHV (NheI: negative)
blaCTX-M
PT-05 1 – blaSHV (NheI: negative)
blaCTX-M
PT-06 1 – blaSHV (NheI: negative)
blaCTX-M
PT-07 1 – blaSHV (NheI: negative)
blaCTX-M
PT-08 1 – blaSHV (NheI: negative)
blaCTX-M
PT-09 1 – blaSHV (NheI: negative)
blaCTX-M
PT-10 2 ST1193 blaSHV-5
PT-11 1 ST34 blaSHV-5
PT-12 1 ST113 blaSHV-5
PT-13 1 ST323 blaSHV-5
PT-14 2 – blaSHV (NheI: positive)
blaCTX-M
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Table II. Number of patients infected or colonized 
by ESBL producing K. pneumoniae isolates detected at the Clinical Centre University of Pécs 















2004  16   2  0  1 0  1
2005  34   9  4  5 0  0
2006  78  17 12  3 0  2
2007  70  47 37  1 2  7
2008  74  27 16  0 7  4
Total 272 102 69 10 9 14
Table III. Number of patients infected or colonized 
by ESBL producing K. pneumoniae isolates detected at the Clinical Centre University of Pécs 
















 22  11  6  0 0  5
Internal Medicine 1  92  40 27  9 1  3
Internal Medicine 2  18   5  3  1 1  0
Neurology  23   3  2  0 0  1
Surgery  14   3  3  0 0  0
Urology  79  35 27  0 6  2
Other  24   5  1  0 1  3
Total 272 102 69 10 9 14













amikacin 51 (74%) 3 (30%) 8 (89%) 8 (57%) 0.018
gentamicin 11 (16%) 0 (0%) 1 (11%) 0 (0%) 0.070
tobramycin  4 (6%) 0 (0%) 0 (0%) 0 (0%) 0.361
trimethoprim / sulfamethoxazole 38 (55%) 1 (10%) 0 (0%) 9 (64%) <0.001
ciprofl oxacin disc diffusion  0 (0%) 0 (0%) 0 (0%) 9 (64%) <0.001
MIC range ≥32 mg/L ≥32 mg/L 4–32 mg/L 0.06–32 mg/L
*P-values were calculated to test whether antimicrobial susceptibility were independent of the clonal 
grouping.
 ST101 K. PNEUMONIAE CLONE IN HUNGARY 239
Acta Microbiologica et Immunologica Hungarica 62, 2015














string-test  2 (3%)  0 (0%)  0 (0%)  2 (14%) 0.245
rmpA  0 (0%)  0 (0%)  0 (0%)  0 (0%) –
magA  0 (0%)  0 (0%)  0 (0%)  0 (0%) –
k2a  0 (0%)  0 (0%)  0 (0%)  0 (0%) –
enterobactin 67 (97%)  5 (50%)  6 (67%) 14 (100%) <0.001
aerobactin  1 (1%)  0 (0%)  0 (0%)  1 (7%) 0.566
kfuB 69 (100%) 10 (100%)  0 (0%)  3 (21%) <0.001
irp2-1  0 (0%) 10 (100%)  0 (0%)  2 (14%) <0.001
type 1 fi mbria 67 (99%)** 10 (100%)  9 (100%) 13 (93%) 0.833
type 3 fi mbria 65 (96%)**  4 (40%)  6 (67%)  6 (46%) <0.001
biofi lm formation 67 (97%) 10 (100%)  9 (100%)  8 (57%) <0.001
biofi lm (median of OD)  3.526  2.112  2.463  1.262 <0.001
serum resistance at 60 min (median) 15.20%  5.40% 62.11%  1.46% 0.005
serum resistance at 180 min 
(median)
 4.41%  4.09%  8.86%  0.09% 0.087
*P-values were calculated to test whether virulence associated trait possession were independent of the 
clonal grouping.
**n = 68. One isolate showed autoaggregative properties.
Discussion
Our results show the complexity, and present the local characteristics of 
molecular epidemiology of ESBL producing K. pneumoniae in our institution.
Beside several minor clones, three internationally disseminated CTX-M-15 
producing K. pneumoniae clones, namely ST15, ST101 and ST147 were present in 
the Clinical Centre University of Pécs, of which ST15 and ST147 are considered 
to be epidemic clones in Hungary [6, 32–36].
Until now the presence of ST101 was not reported in Hungary. This se-
quence type was associated with various β-lactam resistance mechanisms in dif-
ferent parts of the world: CTX-M-15 production in France, Greece and Italy; 
SHV-12 production in the Czech Republic; OXA-48 production in Spain, Libya, 
France, Tunisia, Morocco, Switzerland and South Africa; KPC-2 production in 
Italy and Spain [32, 35–42]. In our institution the presence of CTX-M-15 produc-
ing ST101 seemed to be restricted both timely and spatially, as the majority of 
the isolates originated from a single department with a decreasing incidence 
( Tables II and III).
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Beside blaCTX-M-15 detected in major clones one additional ESBL gene 
(blaSHV-5) was identifi ed in this study. The blaSHV-5 gene was harboured by four 
distinct minor clones (ST34, ST113, ST323 and ST1193). Among them ST1193 
was identifi ed as a new sequence type (allelic profi le: 2-83-2-1-9-4-135), and har-
boured a novel variant of the infB allele (designated as number 83). The new se-
quence type and infB allele were deposited and are publicly available at the MLST 
database of Institut Pasteur, Paris, France (bigsdb.web.pasteur.fr).
Considering the distribution in time and place (Tables II and III), several 
clonal characteristics could be assumed. Presumably ST101 was the dominant 
clone in our institution between 2004 and 2005, and its dissemination was main-
ly confi ned to Internal Medicine 1 and 2. ST15 might have emerged during the 
initial period of our study, and later became the predominant ESBL producing 
clone of our institution affecting the majority of the departments. The dissemina-
tion of ST147 supposedly started around 2007, and since then it has spread to 
several departments of the Clinical Centre. Minor clones were most commonly 
detected at the Department of Anaesthesia and Intensive Therapy and at other 
smaller departments.
Although we did not have the possibility to investigate every isolate origi-
nating from our institution, and for nine minor clone isolates the exact type of 
ESBL was not identifi ed, but local characteristics in the molecular epidemiology 
of ESBL producing K. pneumoniae isolates could be presumed when comparing 
our fi ndings to national data. Two of the epidemic clones described (ST11 and 
ST274) were not observed during our study period, and despite widespread dis-
semination of ST147 across the country in 2005, it was only detected fi rst in 2007 
in our institution possibly due to later importation or low incidence rates [6, 7]. 
According to our investigations ST15 and CTX-M-15 β-lactamases were the 
dominant clone and ESBL type in our institution, which matches with national 
data [6]. Of the SHV-type ESBL genes examined, only blaSHV-5 was found, which 
is in agreement with the result of a nationwide study [4].
Considering the results of antimicrobial susceptibility testing it can be con-
cluded that non-susceptibility to gentamicin and tobramycin was common for 
major and minor clone isolates as well. The rate of susceptibility to amikacin and 
trimethoprim/sulfamethoxazole varied among different clones. While the CTX-
M-15 producing major clone isolates were universally resistant to ciprofl oxacin, 
the majority (64%) of minor clones were susceptible to this compound. The rate 
of susceptibility was even higher (80%), when only SHV-5 producing isolates 
were taken into account. Corresponding to susceptibility rates, the range of MIC 
values also showed considerable differences (ST15: ≥32 mg/L; ST101: ≥32mg/L; 
ST147: 4–32 mg/L; SHV-5 producing minor clones: 0.06–2 mg/L). Dissimilari-
ties in the level of resistance to ciprofl oxacin was suggested to be infl uenced by 
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variability in fi tness cost associated with the acquisition of fl uoroquinolone re-
sistance, and it was indicated that SHV-type ESBL plasmids might be lost during 
the induction of high level fl uoroquinolone resistance [43]. Correspondingly high 
level ciprofl oxacin resistance was not observed in SHV-5 producing isolates in 
our study. The only resistant isolate showed low level resistance (MIC = 2 mg/L), 
and belonged to ST113.
In our study high rate of type 1 fi mbria expression and peculiar siderophore 
content were characteristic for each clone. All the major clones (ST15, ST101 and 
ST147) showed high biofi lm forming capacity. ST147 was the least susceptible 
clone to bactericidal activity of human serum. While some studies indicated that 
ESBL producing K. pneumoniae isolates (1) had higher rates of co-expression of 
type 1 and type 3 fi mbria, (2) were more resistant to serum bactericidal activity 
or (3) showed increased adherence to and invasion of human epithelial cells, than 
non-ESBL producing ones, other studies suggested that different virulence fac-
tors might be associated with distinct clones or resistance plasmids [8–12, 44, 
45]. Our results also imply that the distribution of virulence associated traits 
might be diverse among different ESBL producing K. pneumoniae clones.
The ongoing dissemination of internationally successful multiresistant 
clones and epidemic resistance plasmids in addition to emergence of new antibi-
otic resistance mechanisms make continuous surveillance and study of molecular 
epidemiology of multiresistant bacteria mandatory.
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